Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25120828 | 0.92 | GPR84 (0.44) | PGAM1ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL13412631 | 0.76 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19PDE3BPDE3A | |
| SCHEMBL9852469 | 0.75 | HTR1B (0.44) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL30485171 | 0.72 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| Squaric Acid Dibutyl Ester SCHEMBL56180 | 0.72 | CYP3A4 (0.44) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL30485172 | 0.72 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL7755326 | 0.72 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL16005863 | 0.71 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL12434156 | 0.70 | ESR1 (0.49) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL6901164 | 0.70 | LMNA (0.40) | CYP1A2CYP2C9CYP2C19PGAM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998608-B2 | Polysaccharide and methods | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (GB) | 2024-06-04 | — | — | US | disclosed |
| CN-110072872-B | Vaccine for preventing infection caused by Brucella organisms | 环境、食品及农村国务部 | 2024-01-16 | — | — | CN | disclosed |
| US-6211220-B1 | ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1994029277-A1 | AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-22 | — | — | WO | disclosed |
| US-4092146-A | POSTEMERGENCE HERBICIDES, PLANT GROWTH INHIBITORS, DESSICANTS, ETHERS OF CYCLOBUTENEDIONE | CIBA-GEIGY CORPORATION (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998608-B2 | Polysaccharide and methods | CAP1, C1S, DDOST | CYP1A2 4673/4885CYP2C9 3985/4885CYP2C19 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.